ASCO 2020：11项中国科学研究入选口头报告，17项Poster报告

不受全球性新近冠疫情严重影响，原定于5月末29日~6月末2日在芝加哥出席的美国诊断学才会（ASCO）年才会今年将首次以本站上基本概念举办，这是现有最大规模的本站上盛才会。今天，才决议的简述题目出炉，总共103个sessions，西方总一共11项学术研究获选口头报告，17项获选Poster

Pyrotinib or lapatinib plus capecitabine for HER2+ metastatic breast cancer (PHOEBE): A randomized phase III trial.Session: Breast Cancer—MetastaticAuthor(s): Binghe Xu, Min Yan, Fei Ma, Xi-Chun Hu, Ji Feng Feng, Quchang Ouyang, Zhongsheng Tong, Huiping Li, Qingyuan Zhang, Tao Sun, Xian Wang, Yongmei Yin, Ying Cheng, Wei Li, Xiaoyu Zhu, Chunxia Chen, Jianjun ZouAbstract: 1003

吡咯替尼或帕尔马替尼加卡培他平野用以HER2+心肌梗死前列腺帕金森氏症（PHOEBE）：一项III期随机试验性。

演奏才会：心肌梗死前列腺帕金森氏症

笔记：西方医学科学院该医院徐兵河系主任、马飞系主任，复旦大学另设该医院胡夕春系主任等

简述号：1003

Phase III trial of metronomic capecitabine maintenance after standard treatment in operable triple-negative breast cancer (SYSUCC-001).

Session: Breast Cancer—Local/Regional/Adjuvant

Author(s): XI Wang, Shu-Sen Wang, Heng Huang, Li Cai, Rou-Jun Peng, Li Zhao, Ying Lin, Jian Zeng, Le-Hong Zhang, Yong-Li Ke, Xian-Ming Wang, Xin-Mei Liu, Qian-Jun Chen, An-Qin Zhang, Dan-Mei Pang, Fei Xu, Jia J. Huang, Yanxia Shi, Jun Tang, Zhongyu Yuan

Abstract: 507

可手术三阴性前列腺帕金森氏症标准病人后卡培他平野维持旋律治疗的III期试验性（SYSUCC-001）。

演奏才会：前列腺帕金森氏症—局部/地带/来进行病人

笔记：中的山大学防治中的心王时树森系主任等

简述号：507

Utilizing phenotypic characteristics of metastatic brain tumors to predict the probability of circulating tumor DNA detection from cerebrospinal fluid.Session: New Tools to Combat Old FoesAuthor(s): Meichen Li, Delan Li, Xue Hou, Xiangheng Zhang, Na Wang, Jianzhong Liang, Jing Chen, Kaicheng Wang, Fufeng Wang, Yedan Chen, Xian Zhang, Hua Bao, Xue Wu, Xiaonan Wang, Yang Shao, Likun ChenAbstract: 2507

利用心肌梗死脑的表型特征来预测脑脊液中的循环DNA检测的机率: 新近机器对抗据说获胜

演奏才会：新近机器彻底解决据说问题

笔记：李美芹 李德兰等

简述号: 2507

Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase II/III trial.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Feng Bi, Shukui Qin, Shanzhi Gu, Yuxian Bai, Zhendong Chen, Zishu Wang, Jieer Ying, Yinying Lu, Zhiqiang Meng, Hongming Pan, Ping Yang, Helong Zhang, Xi Chen, Aibing Xu, Xiufeng Liu, Qiu Meng, Liqing Wu, Feng Chen

Abstract: 4506

多纳非尼对里拉拉非尼作为后半期肝细胞才会帕金森氏症的一本站病人：一项开放日首页、随机、多中的心II/III期试验性。

演奏才会：肾脏帕金森氏症—胃部食管、癌变和绝

笔记：东南大学索科利夫卡该医院毕锋系主任、西方当权者解放军新近华该医院秦叔逵系主任等

简述号：4506

Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma: A randomized, placebo-controlled, double-blind, phase III study.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Qiu Li, Shukui Qin, Shanzhi Gu, Xiaoming Chen, Lizhu Lin, Zishu Wang, Aibing Xu, Xi Chen, Cuncai Zhou, Zhenggang Ren, Lin Yang, Li Xu, Yuxian Bai, Lei Chen, Jun Li, Hongming Pan, Bangwei Cao, Weijia Fang, Ping Yan, Chunlei Jin

Abstract: 4507

西方后半期肝帕金森氏症病变阿帕替尼二本站病人：一项随机、安慰剂相比较、随机对照III期学术研究

演奏才会：肾脏帕金森氏症—胃部食管、癌变和绝

笔记：西方当权者解放军新近华该医院秦叔逵系主任、东南大学索科利夫卡该医院李秋系主任等

简述号：4507

A randomized phase III trial of secondary cytoreductive surgery in later recurrent ovarian cancer: SOC1/SGOG-OV2.

Session: Gynecologic Cancer

Author(s): Rongyu Zang, Jianqing Zhu, Tingyan Shi, Jihong Liu, Dongsheng Tu, Sheng Yin, Rong Jiang, Ping Zhang, Huixun Jia, Yuting Luan, Yuqin Zhang, Xiaojun Chen, Xiao Huang, Wenjuan Tian, Wen Gao, Yanling Feng, Huijuan Yang, Xi Cheng, Yulang Cai

Abstract: 6001

后半期发作性脑肉瘤症二次细胞才会减灭术的一项随机III期试验性：SOC1 / SGOG-OV2。

为题：妇科帕金森氏症症

笔记：复旦大学另设中的山该医院臧荣余系主任等

简述：6001

Sequential chemoradiation versus radiation alone or concurrent chemoradiation in adjuvant treatment after radical hysterectomy for stage IB1-IIA2 cervical cancer (STARS Study): A randomized, controlled, open-label, phase III trial.

Session: Gynecologic Cancer

Author(s): He Huang, Yanling Feng, Ting Wan, Yanna Zhang, Xinping Cao, Yongwen Huang, Ying Xiong, Xin Huang, Min Zheng, Yanfang Li, Jundong Li, Guandi Chen, Hu Li, Yile Chen, Liguo Ma, Hongying Yang, Li Li, Shuzhong Yao, Qing Liu, Jihong Liu

Abstract: 6007

IB1-IIA2期宫颈帕金森氏症根治性子宫切除术后来进行病人中的的序贯放治疗对比基本上PET或实时放治疗（STARS学术研究）：一项随机、相比较、开放日首页的III期试验性。

才决议：妇科帕金森氏症症

笔记：中的山大学防治中的心黄鹤系主任、刘继红系主任等

简述号：6007

CTONG1104: Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation—Final overall survival ysis of the randomized phase III trial 1 ysis of the randomized phase III trial.

Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Author(s): Yi-Long Wu, Wenzhao Zhong, Qun Wang, Weimin Mao, Song-Tao Xu, Lin Wu, Chun Chen, Ying Cheng, Lin Xu, Jun Wang, Xiao-Fei Li, Jian Li, Cheng Huang, Zhidong Liu, Shun Xu, Jin-Ji Yang, Hong-Hong Yan, Xue-Ning Yang, Si-yang Liu, Qing Zhou

Abstract: 9005

CTONG1104：来进行吉非替尼对比治疗用以可切除的EGFR基因的N1-N2期NSCLC-随机III期诊断试验性的最终基本上生存比对。

为题：帕金森氏症症—非小细胞才会局部-地带/小细胞才会/其他面部

笔记：佛山市当权者该医院吴一龙系主任等

简述号：9005

First-line tyrosine kinase inhibitor with or without aggressive upfront local radiation therapy in patients with EGFRm oligometastatic non-small cell lung cancer: Interim results of a randomized phase III, open-label clinical trial (SINDAS) (NCT02893332).

Session: Lung Cancer—Non-Small Cell Metastatic

Author(s): Xiaoshan Wang, Ming Zeng

Abstract: 9508

EGFR基因少移出非小细胞才会帕金森氏症症病变一本站赖氨酸蛋白激酶抗病毒联合或不联合积极前本站局部PET：III期开放日首页诊断随机试验性（SINDAS）的中的期结果（NCT02893332）。

为题：帕金森氏症症-非小细胞才会移出

笔记：泸州当权者该医院曾铭系主任等

简述：9508

Overall survival and biomarker ysis of a phase Ib combination study of toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) with axitinib in patients with metastatic mucosal melanoma.

Session: Melanoma/Skin Cancers

Author(s): Xinan Sheng, Xieqiao Yan, Zhihong Chi, Lu Si, Chuanliang Cui, Bixia Tang, Siming Li, Lili Mao, BIN LIAN, Xuan Wang, Xue Bai, Li Zhou, Yan Kong, Jie Dai, Keith Flaherty, Jun Guo

Abstract: 10007

Toripalimab，一种针对自然而然死亡-1（PD-1）的人源化IgG4化学疗法联合阿昔替尼用以心肌梗死皮肤黑色素肉瘤病变的Ib期学术研究的总生存期和生物遥相呼应比对。

为题：黑色素肉瘤/皮肤帕金森氏症

笔记：北京师范大学该医院郭军、盛锡楠系主任等

简述：10007

Safety and efficacy results of GC027: The first-in-human, universal CAR-T cell therapy for relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL).Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Xinxin Wang, Shiqi Li, Lei Gao, Zhongtao Yuan, Kun Wu, Lin Liu, Le Luo, Yao Liu, Cheng Zhang, Jia Liu, Chunhui Yang, Yu Li, Jiaping He, Xun Ye, Zhimin Li, Xu Tan, Jianning Ge, Wei Cao, Sanbin Wang, Xi ZhangAbstract: 3013Poster: 77 GC027的实用性和结果：国际标准化组织CAR-T细胞才会首次人体内试验性病人发作/难治性T细胞才会急性免疫球蛋白才会肺炎（r/r T-ALL）的实用性和。才决议：合作开发中的的病人技术开发-免疫病人。笔记：王时岂料等简述：3013贴纸：77 Sintilimab in patients with advanced esophageal squamous cell carcinoma refractory to previous chemotherapy: A randomized, open-label phase II trial (ORIENT-2).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Jianming Xu, Yi Li, Qingxia Fan, Yongqian Shu, Zhijun Wu, Tongjian Cui, Kangsheng Gu, Min Tao, Xiuwen Wang, Chengxu Cui, Nong Xu, Juxiang Xiao, Quanli Gao, Yunpeng Liu, Tao Zhang, Hui Zhou, Yan Wang, Linxinyu Xu, Zhuo Ma, Yanqi WangAbstract: 4511Poster: 119 信迪利单抗在后半期食管表皮细胞才会帕金森氏症病变中的的分析方法：一项随机的开放日首页II期试验性（ORIENT-2）。才决议：肾脏帕金森氏症-胃部食管帕金森氏症、癌变帕金森氏症和绝道帕金森氏症笔记：徐建明系主任等简述：4511贴纸：119 Eradication of medulloblastoma by NKG2D-specific CAR T-cells.Session: Central Nervous System TumorsAuthor(s): Hong-jiu Dai, Bin Sun, Dong Yang, Hui Xu, Jingjing Zhu, Jia Wei, Xudong ZhaoAbstract: 2522Poster: 13 NKG2D依赖性CAR-T细胞才会对炎母细胞才会肉瘤的扫除性病人才决议：中的枢神经系统笔记：代红久、孙斌、杨东、徐晖、朱晶晶、魏佳、姚旭东简述：2522贴纸。13 Envafolimab (KN035) in advanced tumors with mismatch-repair deficiency.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Lin Shen, Jian Li, Yanhong Deng, Weijie Zhang, Aiping Zhou, Weijian Guo, Jianwei Yang, Ying Yuan, Liangjun Zhu, Shukui Qin, Silong Xiang, Haolan Lu, John Gong, Ting Xu, Did LiuAbstract: 3021Poster: 85 Envafolimab（KN035）在后半期错配修复缺陷病变中的的分析方法才决议：合作开发中的的病人学-免疫病人笔记：沈琳系主任等简述：3021贴纸。85 First-in-human clinical trial of the autologous CD7-CART for relapsed/refractory ACUTE lymphoblastic leukemia/lymphoma.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Mingzhi Zhang, Lin Yang, Xiaorui Fu, Lei Zhang, Huimin Meng, Ling Li, Xin Li, Xinhua Wang, Zhenchang Sun, Hui Yu, Zhaoming Li, Feifei Nan, Yu Chang, Zhiyuan Zhou, Jiaqin Yan, Jiwei Li, Min Wang, Fengtao You, Yu-Sheng Chen, Bozhen ZhangAbstract: 3026Poster: 90 自体CD7-CART病人发作/难治性ACUTE免疫球蛋白才会肺炎/乳腺癌的首例人体内诊断试验性才决议: 合作开发性病人学-免疫病人笔记简介：张明志，南部县等简述：3026贴纸: 90 A phase Ib study of simmitecan (LP) single-agent and in combination with 5-fluorouracil/leucovorin (5-FU/LV) or thalidomide (T) in patients with advanced solid tumor.Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor BiologyAuthor(s): Jifang Gong, Ting Deng, Jie Li, Ming Lu, Jian Li, Yi Ba, Qiuqiong Yu, Lin ShenAbstract: 3523Poster: 253 科克替康（LP）单药和5-氟尿嘧啶/白藜芦醇（5-FU/LV）或沙利度胺（T）联合分析方法于后半期实体肉瘤病变的Ib期学术研究才决议：发展性病人学---分子可核酸药物和免疫学笔记：龚继芳，沈琳系主任等简述：3523贴纸：253 A phase II study of rh-endostatin combined with paclitaxel and nedaplatin in treating patients with recurrent or metastatic esophageal squamous cell carcinoma (ESCC).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Zhiqiang Wang, Yu-Hong Li, De-Shen Wang, Fenghua Wang, Chao Ren, Qiong TanAbstract: 4522Poster: 130 Rh-endostatin联合紫杉醇和nedaplatin病人发作性或心肌梗死食管表皮细胞才会帕金森氏症（ESCC）病变的II期学术研究。才决议：肾脏帕金森氏症-胃部食管、癌变和绝道帕金森氏症的学术研究笔记：王时志强，李玉红，王时德申，王时凤华，任超，谭琼 王时志强、李玉红、王时德深、王时凤华、任超、谭琼简述：4522贴纸：130 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Yan Song, Ning Li, Lan Mu, Shu Zhang, Qingxia Fan, Xinjun Liang, Xianli Yin, Zhixiang Zhuang, Yunpeng Liu, Jingdong Zhang, Xiaoge Kou, Haijun Zhong, Jing HuangAbstract: 4524Poster: 132 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.才决议：肾脏帕金森氏症-胃部食管帕金森氏症、癌变帕金森氏症和绝管帕金森氏症的二本站病人笔记：宋艳等简述：4524贴纸：132 A urine exosomal circRNA classifier for detection of high-grade prostate cancer at initial biopsy: A multicenter, retrospective study.Session: Genitourinary Cancer—Prostate, Testicular, and PenileAuthor(s): Liaoyuan Li, Wen Tao, Yadi He, Tao He, Qing Li, Zhenquan Wu, Weiming Deng, Lingxiao ZhangAbstract: 5522Poster: 103 一种排泄物外体外缘RNA均值用以初始活检时检测高等级帕金森氏症的排泄物外体外缘RNA均值：一项多中的心的回顾性学术研究才决议：泌尿生殖系统帕金森氏症症----帕金森氏症、皮肤帕金森氏症和帕金森氏症笔记简介：Liaoyuan Li等简述：5522贴纸。103 Adjuvant chemotherapy after concurrent chemoradiation therapy for locally advanced cervical cancer.Session: Gynecologic CancerAuthor(s): Lingna Kou, Tao Zhang, Siyun Peng, Yifei Wang, Mingyang Yuan, Minmin LiAbstract: 6031Poster: 202 局部后半期宫颈帕金森氏症并发治疗后的来进行治疗才决议: 妇科帕金森氏症症笔记简介： 李珉珉等简述：6031贴纸：202 Association between calcitonin and efficacy of anlotinib in medullary thyroid carcinoma: An ysis based on the ALTER01031 trial.Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Pingzhang Tang, Zhengang Xu, Xiangqian Zheng, Dapeng Li, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6526Poster: 187 降钙素与安罗替尼病人肿肉瘤炎性帕金森氏症的表征：基于ALTER01031试验性的比对。才会话：多毛笔记：天津该医院高明系主任简述：6526贴纸。187 Influence of Eastern Cooperative Oncology Group performance status (ECOG PS), tumor size and age on patient outcomes after anlotinib treatment: A subgroup ysis based on ALTER01031 trial for medullary thyroid carcinoma (MTC).Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Xiangqian Zheng, Dapeng Li, Pingzhang Tang, Zhengang Xu, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6527Poster: 188 ECOG PS、微小和年龄对安洛替尼病人后病变结局的严重影响: ALTER01031的亚组比对才决议：多毛笔记：天津该医院高明系主任简述：6527贴纸。188 Circulating tumor DNA (ctDNA) ysis predicts recurrence following surgery in patients with stage I-IIIA non-small-cell lung cancer (NSCLC): Results of GASTO1035 and GASTO1018.Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic CancersAuthor(s): Si-Yu Wang, Ning Li, Wei Ou, Chao Cheng, Peng-Peng Kuang, Hui-Qi WuAbstract: 9023Poster: 216 ctDNA比对预测I-IIIA期非小细胞才会帕金森氏症症（NSCLC）病变术后发作: GASTO1035和GASTO1018的结果才决议：帕金森氏症症-非小细胞才会局部-地方性/小细胞才会/小细胞才会/其他胸科帕金森氏症症笔记：Si-Yu Wang等简述：9023贴纸：216 Exon-16-skipping ERBB2 (ERBB2ΔEx16) as a novel resistance mechanism against EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC).Session: Lung Cancer—Non-Small Cell MetastaticAuthor(s): Xin Zhao, Linling Jin, Man Yu, Qiuxiang Ou, Hua Bao, Xue Wu, Yang Shao, Min FanAbstract: 9528Poster: 294 ERBB2ΔEx16作为非小细胞才会帕金森氏症症（NSCLC）中的EGFR赖氨酸蛋白激酶抗病毒的新近型细菌性机制才决议:帕金森氏症症-非小细胞才会心肌梗死帕金森氏症症笔记简介：姚昕，金艾利，满宇，欧赛金花，宝珠，薛武，杨少，范敏 姚昕、金艾利、满宇、欧赛金花、宝珠、薛武、杨绍、范敏简述：9528贴纸：294 Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma.Session: Melanoma/Skin CancersAuthor(s): Run-Cong Nie, Shu-Qiang Yuan, Yuanfang Li, Yingbo Chen, Zhiwei ZhouAbstract: 10030Poster: 379 PD-1/PD-L1试验性中的后半期黑色素肉瘤总生存的替代西端才决议：黑色素肉瘤/皮肤帕金森氏症笔记：聂润聪，袁书强，李元芳，陈英波，周志伟 聂润聪、袁书强、李元芳、陈英波、周志伟简述：10030贴纸：379 A phase II study of anlotinib in treating patients with relapsed or metastatic primary malignant bone tumor.Session: SarcomaAuthor(s): Lina Tang, Xiaohui Niu, Zhen Wang, Qiqing Cai, Chongqi Tu, Zhengfu Fan, Yang YaoAbstract: 11525Poster: 413 安罗替尼病人发作或心肌梗死原发性恶性骨病变的II期学术研究才决议： 性疾病笔记：唐丽娜，牛晓辉，王时震，蔡启清，涂崇奇，范正福，杨瑶 唐丽娜、牛晓辉、王时振、蔡启庆、涂崇奇、范正福、杨瑶简述：11525贴纸。413 Preliminary evaluate the safety and efficacy of anlotinib in advanced sarcoma patients in multi-line therapy.Session: SarcomaAuthor(s): Yao Weitao, Jiaqiang Wang, Peng Zhang, Xin Wang, Xinhui Du, Zhichao Tian, Xiaoying NiuAbstract: 11526Poster: 414 初步评价安罗替尼在后半期性疾病病变多本站病人中的的实用性和。才决议：性疾病笔记：姚伟涛，王时家强，王永，王时欣，杜新近辉，田志浩，牛晓颖 姚伟涛、王时家强、王永、王时鑫、杜鑫辉、田志超、牛晓英简述：11526贴纸：414